ATE477279T1 - Ganglioside-assozierte rekombinante antikörper und deren gebrauch fuer diagnose und therapien von tumoren - Google Patents

Ganglioside-assozierte rekombinante antikörper und deren gebrauch fuer diagnose und therapien von tumoren

Info

Publication number
ATE477279T1
ATE477279T1 AT06076643T AT06076643T ATE477279T1 AT E477279 T1 ATE477279 T1 AT E477279T1 AT 06076643 T AT06076643 T AT 06076643T AT 06076643 T AT06076643 T AT 06076643T AT E477279 T1 ATE477279 T1 AT E477279T1
Authority
AT
Austria
Prior art keywords
ganglioside
therapies
tumors
diagnosis
recombinant antibodies
Prior art date
Application number
AT06076643T
Other languages
English (en)
Inventor
De Acosta Del Rio Cristina Maria Mateo
Valladares J Lombardero
Navarro Lourdes Tatiana Roque
Requena Alejandro Lopez
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Application granted granted Critical
Publication of ATE477279T1 publication Critical patent/ATE477279T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
AT06076643T 2001-04-06 2002-04-08 Ganglioside-assozierte rekombinante antikörper und deren gebrauch fuer diagnose und therapien von tumoren ATE477279T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2001008420010084A CU23007A1 (es) 2001-04-06 2001-04-06 Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos

Publications (1)

Publication Number Publication Date
ATE477279T1 true ATE477279T1 (de) 2010-08-15

Family

ID=40291118

Family Applications (3)

Application Number Title Priority Date Filing Date
AT02759751T ATE406386T1 (de) 2001-04-06 2002-04-08 Immunotherapeutische kombinationen zur behandlung von tumoren, die ganglioside überexprimieren
AT02759752T ATE378356T1 (de) 2001-04-06 2002-04-08 Gangliosid-assoziierte rekombinante antikörper und deren verwendung bei der diagnose und behandlung von tumoren
AT06076643T ATE477279T1 (de) 2001-04-06 2002-04-08 Ganglioside-assozierte rekombinante antikörper und deren gebrauch fuer diagnose und therapien von tumoren

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT02759751T ATE406386T1 (de) 2001-04-06 2002-04-08 Immunotherapeutische kombinationen zur behandlung von tumoren, die ganglioside überexprimieren
AT02759752T ATE378356T1 (de) 2001-04-06 2002-04-08 Gangliosid-assoziierte rekombinante antikörper und deren verwendung bei der diagnose und behandlung von tumoren

Country Status (37)

Country Link
US (3) US20050069535A1 (de)
EP (3) EP1798243B1 (de)
JP (2) JP4366080B2 (de)
KR (3) KR100863509B1 (de)
CN (3) CN101054417B (de)
AR (2) AR033123A1 (de)
AT (3) ATE406386T1 (de)
AU (3) AU2002308347B2 (de)
BG (2) BG66304B1 (de)
BR (3) BRPI0208675B1 (de)
CA (2) CA2443372C (de)
CU (1) CU23007A1 (de)
CZ (2) CZ296276B6 (de)
DE (2) DE60228561D1 (de)
DK (2) DK1411064T3 (de)
EA (2) EA006936B1 (de)
EC (2) ECSP034788A (de)
ES (2) ES2296986T3 (de)
HK (3) HK1066818A1 (de)
HR (2) HRP20030805B1 (de)
HU (2) HU228106B1 (de)
IL (2) IL158246A0 (de)
IS (2) IS6965A (de)
MX (2) MXPA03008739A (de)
MY (3) MY137078A (de)
NO (2) NO20034437L (de)
NZ (2) NZ528599A (de)
PE (1) PE20020972A1 (de)
PL (2) PL208109B1 (de)
PT (2) PT1384726E (de)
SG (1) SG161737A1 (de)
SI (2) SI1384726T1 (de)
SK (2) SK287783B6 (de)
UA (3) UA76745C2 (de)
UY (2) UY27242A1 (de)
WO (2) WO2002081496A2 (de)
ZA (2) ZA200307585B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7297336B2 (en) * 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
DK1853305T3 (en) * 2005-02-04 2014-12-01 Survac Aps Survivin-peptide vaccine
FI20055398A0 (fi) 2005-07-08 2005-07-08 Suomen Punainen Risti Veripalv Menetelmä solupopulaatioiden evaluoimiseksi
BRPI0614366A2 (pt) 2005-08-11 2009-10-06 Arpi Matossian Rogers peptìdeo, anticorpo ou fragmento de anticorpo, anticorpo ou ligante funcionalmente equivalente, molécula de ácido nucleico, vetor, célula hospedeira, métodos para expressar um peptìdeo, um anticorpo ou fragmento de anticorpo, um anticorpo ou ligante equivalente e para tratar uma doença em um paciente, composição farmacêutica, composição de vacina, métodos de vacinação de um indivìduo contra uma doença ou um distúrbio e de diagnose de um indivìduo para a presença de anticorpos autoimunes, e, arranjo de peptìdeos
ES2534760T3 (es) * 2005-08-19 2015-04-28 Wyeth Llc Anticuerpos antagonistas contra GDF-8 y sus usos en el tratamiento de ELA y otros trastornos asociados con GDF-8
ITFI20060163A1 (it) * 2006-06-29 2006-09-28 Menarini Internat Operations Luxembourg Sa Composizione farmaceutica contenente un anticorpo monoclonale anti idiotipico anti-ca-125 ed alluminio
TWI434855B (zh) * 2006-11-21 2014-04-21 Hoffmann La Roche 結合物及其在免疫分析中作為參考標準之用途
JP5465542B2 (ja) * 2008-02-22 2014-04-09 片山化学工業株式会社 合成糖脂質含有リポソーム
EP2166085A1 (de) 2008-07-16 2010-03-24 Suomen Punainen Risti Veripalvelu Divalente modifizierte Zellen
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
CN104877026B (zh) 2009-03-10 2019-10-25 比奥根Ma公司 抗-bcma抗体
AU2010236787A1 (en) * 2009-04-01 2011-11-10 Genentech, Inc. Anti-FcRH5 antibodies and immunoconjugates and methods of use
CU23736A1 (es) * 2009-05-04 2011-11-15 Centro Inmunologia Molecular Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso
EP2473530B1 (de) * 2009-09-03 2015-04-22 Vancouver Biotech Ltd. Monoklonale antikörper gegen gonadotropinfreisetzenden hormonrezeptor
AU2012205663B2 (en) * 2011-01-10 2017-02-02 Emory University Antibodies directed against influenza
CU24070B1 (es) * 2011-12-27 2015-01-29 Ct De Inmunología Molecular Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3)
EP2641916A1 (de) * 2012-03-23 2013-09-25 Centre National de la Recherche Scientifique (C.N.R.S) Neue Antikörper gegen Anti-sPLA2-IIA und Verwendungen damit
JP6433889B2 (ja) 2012-06-15 2018-12-05 ファイザー・インク Ｇｄｆ−８に対する改善された拮抗抗体およびその使用
AR096687A1 (es) 2013-06-24 2016-01-27 Genentech Inc Anticuerpos anti-fcrh5
DK3083689T3 (da) 2013-12-17 2020-08-03 Genentech Inc Anti-CD3-antistoffer og fremgangsmåder til anvendelse
WO2015157629A2 (en) * 2014-04-10 2015-10-15 Obi Pharma Inc. Antibodies, pharmaceutical compositions and uses thereof
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
TWI731861B (zh) 2015-06-16 2021-07-01 美商建南德克公司 FcRH5之人源化及親和力成熟抗體及使用方法
WO2018017864A2 (en) * 2016-07-20 2018-01-25 Oncomed Pharmaceuticals, Inc. Pvrig-binding agents and uses thereof
EP3548071A4 (de) 2016-11-30 2020-07-15 OncoMed Pharmaceuticals, Inc. Verfahren zur behandlung von krebs mit tigit-bindenden wirkstoffen
CU20170173A7 (es) * 2017-12-27 2019-11-04 Ct Inmunologia Molecular Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2754206B2 (ja) * 1987-11-17 1998-05-20 メクト株式会社 α２→３結合を認識するモノクローナル抗体
US6051225A (en) * 1988-10-19 2000-04-18 The Dow Chemical Company Family of high affinity, modified antibodies for cancer treatment
DK0586002T3 (da) * 1992-08-18 2000-06-19 Centro Inmunologia Molecular Monoklonale antistoffer, som genkender epidermisvækstfaktor-receptoren, celler og fremgangsmåder heraf og præparater indeho
JPH07101999A (ja) * 1993-10-06 1995-04-18 Hagiwara Yoshihide 抗癌ヒトモノクローナル抗体に対する抗イデイオタイプ抗体のアミノ酸配列およびそれをコードするｄｎａ塩基配列
CU22702A1 (es) * 1997-10-21 2001-07-31 Centro Inmunologia Molecular Anticuerpos monoclonales anti - idiotipo, su uso en la inmunoterapia activa de tumores malignos, hibridoma que los produce y composiciones que los contienen
US6063379A (en) * 1993-12-09 2000-05-16 Centro De Inmunologia Molecular Anti-idiotypic monoclonal antibodies and compositions including the anti-idiotypic monoclonal antibodies
DE69428763T2 (de) * 1993-12-09 2002-08-01 Ct De Inmunologia Molecular Ci Monoklonale Antikörper gegen Ganglioside und deren Verwendung in der spezifischen, aktiven Immuntherapie gegen bösartige Tumoren
CU22420A1 (es) * 1993-12-29 1996-01-31 Centro Inmunologia Molecular Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer
US6149921A (en) * 1993-12-29 2000-11-21 Centro De Inmunologia Molecular Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
CU22731A1 (es) * 1998-02-05 2002-02-28 Centro Inmunologia Molecular Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies

Also Published As

Publication number Publication date
WO2002081661A2 (es) 2002-10-17
CN1507452A (zh) 2004-06-23
BR0208676B1 (pt) 2017-11-14
US20050069535A1 (en) 2005-03-31
HUP0401355A3 (en) 2012-05-29
MY145703A (en) 2012-03-30
UY27242A1 (es) 2002-07-31
DE60228561D1 (de) 2008-10-09
NO331533B1 (no) 2012-01-23
ATE378356T1 (de) 2007-11-15
BG108228A (bg) 2005-04-30
NO20034437L (no) 2003-12-02
UA75393C2 (en) 2006-04-17
BR0208675A (pt) 2004-08-03
AR033123A1 (es) 2003-12-03
SK12162003A3 (sk) 2004-05-04
CA2441845A1 (en) 2002-10-17
MY137078A (en) 2008-12-31
CZ296276B6 (cs) 2006-02-15
CU23007A1 (es) 2004-12-17
IL158246A0 (en) 2004-05-12
ES2296986T3 (es) 2008-05-01
JP4366080B2 (ja) 2009-11-18
ECSP034788A (es) 2004-01-28
JP2004528033A (ja) 2004-09-16
EA006310B1 (ru) 2005-10-27
CA2443372C (en) 2013-05-28
AU2007231687B2 (en) 2010-09-30
IS6965A (is) 2003-09-23
ES2312610T3 (es) 2009-03-01
UY27243A1 (es) 2002-09-30
SI1384726T1 (sl) 2009-04-30
US8758753B2 (en) 2014-06-24
SK287783B6 (sk) 2011-09-05
HRP20030806B1 (en) 2011-11-30
IS2701B (is) 2010-11-15
BG108227A (bg) 2005-04-30
MXPA03008738A (es) 2003-12-11
CZ304424B6 (cs) 2014-04-30
SI1411064T1 (sl) 2008-04-30
PT1384726E (pt) 2008-12-05
AU2002308347B2 (en) 2006-09-14
CZ20032668A3 (cs) 2004-07-14
HUP0401355A2 (hu) 2004-10-28
NZ528599A (en) 2005-03-24
PL371770A1 (en) 2005-06-27
HU228105B1 (en) 2012-11-28
CA2441845C (en) 2011-06-07
AU2007231687A1 (en) 2007-11-22
EP1411064A2 (de) 2004-04-21
HRP20030806A2 (en) 2005-08-31
WO2002081496A3 (es) 2004-02-19
SK12262003A3 (sk) 2004-08-03
UA76745C2 (uk) 2006-09-15
MY157372A (en) 2016-06-15
BG66293B1 (en) 2013-02-28
EP1798243A3 (de) 2007-10-17
BG66304B1 (bg) 2013-03-29
PE20020972A1 (es) 2003-01-02
MXPA03008739A (es) 2003-12-11
ATE406386T1 (de) 2008-09-15
HRP20030805B1 (en) 2011-11-30
ECSP034787A (es) 2004-01-28
AU2002308348B2 (en) 2007-11-22
HK1070080A1 (en) 2005-06-10
CN1535282A (zh) 2004-10-06
HK1109160A1 (en) 2008-05-30
CA2443372A1 (en) 2002-10-17
NO20034436L (no) 2003-12-02
US20040253233A1 (en) 2004-12-16
EA006936B1 (ru) 2006-06-30
HK1066818A1 (de) 2005-04-01
EA200301097A1 (ru) 2004-02-26
KR20030092048A (ko) 2003-12-03
NO20034437D0 (no) 2003-10-03
CN1319991C (zh) 2007-06-06
DE60223547T2 (de) 2008-09-18
PL371937A1 (en) 2005-07-11
SK287914B6 (sk) 2012-03-02
CN100349920C (zh) 2007-11-21
AR033122A1 (es) 2003-12-03
ZA200307679B (en) 2005-03-30
IS6964A (is) 2003-09-23
UA86768C2 (ru) 2009-05-25
NZ528598A (en) 2005-03-24
EP1798243A2 (de) 2007-06-20
EP1798243B1 (de) 2010-08-11
HRP20030805A2 (en) 2005-08-31
WO2002081496A2 (es) 2002-10-17
NO20034436D0 (no) 2003-10-03
PL208109B1 (pl) 2011-03-31
BR0208676A (pt) 2008-04-08
CN101054417A (zh) 2007-10-17
IL158246A (en) 2010-05-31
HU228106B1 (en) 2012-11-28
EA200301098A1 (ru) 2004-04-29
KR20030087053A (ko) 2003-11-12
EP1384726A2 (de) 2004-01-28
DK1411064T3 (da) 2008-03-25
CZ20032641A3 (cs) 2004-07-14
WO2002081661A3 (es) 2003-01-03
DE60223547D1 (de) 2007-12-27
EP1411064B1 (de) 2007-11-14
BRPI0208675B1 (pt) 2018-03-13
KR100919617B1 (ko) 2009-09-29
JP2004525953A (ja) 2004-08-26
KR100863509B1 (ko) 2008-10-15
ZA200307585B (en) 2004-09-16
CN101054417B (zh) 2012-07-11
EP1384726B1 (de) 2008-08-27
KR100946168B1 (ko) 2010-03-11
US20100297008A1 (en) 2010-11-25
KR20080080680A (ko) 2008-09-04
DK1384726T3 (da) 2008-12-15
HUP0401695A3 (en) 2012-05-29
PT1411064E (pt) 2008-02-12
SG161737A1 (en) 2010-06-29
HUP0401695A2 (en) 2006-08-28

Similar Documents

Publication Publication Date Title
ATE477279T1 (de) Ganglioside-assozierte rekombinante antikörper und deren gebrauch fuer diagnose und therapien von tumoren
CY2019022I1 (el) Ανθρωπινα cdr-μοσχευμενα αντισωματα και θραυσματα αντισωματων τους
CY2020003I2 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
ATE402191T1 (de) Rekombinante il-18 antikörper und deren verwendung
DE60233157D1 (de) Zweikammer-herzschrittmacher-system zur diagnose und behebung von arrhythmien
HUP0400284A3 (en) Recombinant tumor specific antibody and use thereof
AU2002308348A1 (en) Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours
DE60230868D1 (de) Criptoblockierende antikörper und deren verwendung
ID28088A (id) Antibodi untuk cd23, turunan-turunannya dan penggunannya untuk terapi
CY2014046I1 (el) Αντισωμα το οποιο δεσμευει αλφα4βητα7 ιντεγκρινη και η χρηση αυτου εις τη θεραπευτικη αγωγη της φλεγμονωδους νοσου του εντερου
ATE412013T1 (de) Anti-osteopontin-antikörper und dessen verwendung
DE69836630D1 (de) Menschliche toll-ähnliche rezeptorproteine, zugehörige reagenzien und verfahren
DE50212615D1 (de) Lyophilisierte zubereitung enthaltend antikörper gegen den egf-rezeptor
PL1623997T3 (pl) Rekombinowane przeciwciała i fragmenty rozpoznające gangliozyd n-glikolilo-gm3 i ich zastosowanie w diagnostyce i leczeniu nowotworów
DE69941344D1 (de) Spezifische Antikörper enthaltende Bindungsproteine die das nekrotische Tumorzentrum binden und deren Verwendung
DE10292329D2 (de) Werkzeuge zur Diagnostik, molekularen Definition und Therapieentwicklung chronischer entzündlicher Gelenkerkrankungen
ATE494307T1 (de) Neoplasma-spezifische antikörper und deren verwendungen
DE3686766D1 (de) Monoklonaler antikoerper gegen glutathion s-transferase und dessen verwendung zur diagnose von krebs.
DE60237322D1 (de) Ganglioside-assozierte rekombinante Antikörper und deren Gebrauch fuer Diagnose und Therapien von Tumoren
DE69800080D1 (de) Antikörper gegen das Prorenin Profragment, reninaktive Substanz die diese enthält und Prorenintest die diese verwendet
DE60014616D1 (de) Antikörper gegen plazentaprotein 13
DE10296200D2 (de) Verfahren zur Diagnose von Brustkrebserkrankungen, zugehörige Peptide und deren Verwendungen
DE10193655D2 (de) Mittel zur Diagnose von Tumoren
IT1293510B1 (it) Anticorpi monoclonali catalitici per la trasformazione in vivo di profarmaci di corticosteroidi
DE60041561D1 (de) Zusammensetzungen und Methoden zur Diagnose von Tumoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties